NASDAQ · QNTM
Healthcare · Drug Manufacturers - Specialty & Generic
$2.21
Up+$0.00 (+0.00%)
Updated Nov 4, 2026, 9:49 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QNTM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
QNTM closed at $2.21 after 21 trading sessions, down 28.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.27 | $2.34 | $2.21 | $2.21 | 45.31K |
| Nov 2, 2026 | $2.41 | $2.4399 | $2.20 | $2.26 | 57.38K |
| Oct 30, 2026 | $2.45 | $2.4708 | $2.29 | $2.38 | 76.83K |
| Oct 29, 2026 | $2.43 | $2.50 | $2.35 | $2.44 | 52.67K |
| Oct 28, 2026 | $2.42 | $2.42 | $2.35 | $2.37 | 103.35K |
| Oct 27, 2026 | $2.21 | $2.40 | $2.17 | $2.32 | 86.83K |
| Oct 26, 2026 | $2.20 | $2.24 | $2.09 | $2.21 | 176.51K |
| Oct 23, 2026 | $2.26 | $2.3662 | $2.24 | $2.24 | 42.71K |
| Oct 22, 2026 | $2.37 | $2.43 | $2.25 | $2.27 | 150.42K |
| Oct 21, 2026 | $2.45 | $2.48 | $2.37 | $2.40 | 90.61K |
| Oct 20, 2026 | $2.42 | $2.55 | $2.408 | $2.43 | 51.74K |
| Oct 19, 2026 | $2.49 | $2.5499 | $2.40 | $2.41 | 63.6K |
| Oct 16, 2026 | $2.68 | $2.7474 | $2.46 | $2.47 | 190.81K |
| Oct 15, 2026 | $2.65 | $2.74 | $2.60 | $2.71 | 107.52K |
| Oct 14, 2026 | $2.85 | $2.8892 | $2.66 | $2.66 | 180.88K |
| Oct 13, 2026 | $2.83 | $2.9699 | $2.80 | $2.89 | 84.86K |
| Oct 12, 2026 | $2.98 | $3.00 | $2.80 | $2.82 | 157.6K |
| Oct 9, 2026 | $3.11 | $3.1101 | $2.94 | $2.94 | 130K |
| Oct 8, 2026 | $3.10 | $3.23 | $3.10 | $3.11 | 78.76K |
| Oct 7, 2026 | $3.07 | $3.16 | $3.02 | $3.145 | 149.46K |
| Oct 6, 2026 | $3.34 | $3.39 | $3.05 | $3.09 | 627.08K |
The latest Smart Investors Daily articles mentioning QNTM.
Company
Market Activity
Research & News
QNTM research
Company profile and research snapshot.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 20, 2026
LOS ANGELES, CA - October 20, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and ...
Benzinga · Oct 20, 2026
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
Yahoo · Oct 14, 2026
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
Yahoo · Oct 8, 2026
Thermo Fisher Scientific (TMO) just appeared in the headlines after its clinical research business signed a Study Start-Up Agreement with Quantum BioPharma to run a Phase 2 multiple sclerosis trial for Lucid-MS. For context, Thermo Fisher Scientific’s share price is at US$662.06, with a 30-day share price return of 7.87% and a 90-day gain of 26.18%, while the 1-year total shareholder return of 23.91% points to momentum that has been building rather than fading. Capitalize on the momentum...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNTM.
No results
No recent SID articles mention QNTM.
